Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Alexion Pharma

Amgen

Biogen

Gilead Sciences

Moderna

Vertex Pharmaceuticals

The short interest data are out for September 30, the most recent settlement date.

Short Sellers Need to Find a Clue on Major Biotechs

Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the novel Coronavirus – is up by 16% year-to-date, compared to the S&P 500 which is up about 4%. While the long-term demand for Covid-19 treatments is not clear.

Regeneron & Gilead: Covid Treatment Stocks Back In Focus As Winter Nears

Pfizer

Zoom Video

Here's why you should catch the rising wave on these three coronavirus stocks.

Buy Alert: These 3 Coronavirus Stocks Are Heading Higher

Abbott Labs

Their coronavirus programs are only part of the attraction for these stocks.

3 Top Coronavirus Stocks to Buy in October

Quest Diagnostics

Emergent BioSolutions

Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.

3 Stocks to Buy No Matter What Happens in November

Eli Lilly

Here's why Americans could soon have access to treatments that prevent mild infections from becoming severe.

Effective Antibody Treatments for COVID-19 Could Be Ready Soon

Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.

Regeneron Gains on EUA Request for Coronavirus Treatment

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail. The experimental drug, named REGN-COV2, was in news last week after it was administered to President Donald Trump.

Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021

The biotech company President Trump credited with helping him fend off the coronavirus is run by two Queens-bred billionaires who still have roots in New York.

Meet the Queens-bred billionaires behind COVID-19 drugmaker Regeneron

Regeneron Pharmaceuticals, boosted by an endorsement from President Trump, filed for emergency authorization for its Covid-19 drug therapy, while Gilead Sciences inked European supply deal. The post Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply Deal appeared first on Investor's Business Daily.

Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply Deal

Shares of Regeneron Pharmaceuticals Inc. were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody treatment. The therapy was prescribed to President Donald Trump last week as part of his COVID-19 treatment plan; on Wednesday, in a video, Trump called it a "cure.

Regeneron's stock rallies after it announces EUA request for antibody treatment

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

West Pharmaceutical Services

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on InvestorPlace.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

TARRYTOWN, N.Y., Oct. 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2020 financial and operating results on Thursday, November 5, 2020, before the U.S. financial markets open. The Company will host a conference...

Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020

Regeneron (REGN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Regeneron (REGN) in Focus: Stock Moves 7.1% Higher

This biotech's COVID-19 program is only part of the story.

This Healthcare Stock Could Keep Crushing the Market

BioNTech SE

The three companies are accused of using a fluorescent protein in their research without paying royalties for it.

Pfizer, BioNTech, and Regeneron Hit With Patent Lawsuits Over COVID-19 Drugs and Vaccines

A famous person received the company's experimental COVID-19 treatment.

Why Regeneron Pharmaceuticals Shot 7% Higher on Monday

Shares of Regeneron Pharmaceuticals (REGN) surged higher on Monday as speculation grew that the FDA will authorize its coronavirus treatment for emergency use.

Why Regeneron Pharmaceuticals Jumped on Monday

Block

Tilray Brands

Aphria

Square, Regeneron, Aphria and Tilray were our top stock trades for Tuesday. That said, here's how the charts look after Monday's action.

4 Top Stock Trades for Tuesday: SQ, REGN, APHA, TLRY

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were advancing Monday following a sell-side upgrade and the news of President Donald Trump being administered its investigational COVID-19 antibody cocktail.

Why Regeneron's Growth Opportunity Is Unappreciated

White House doctors' choice of their therapies to treat President Trump for Covid-19 boosted Regeneron and Gilead shares Monday; an analyst expects FDA approval of Regeneron treatment soon. The post Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President appeared first on Investor's Business Daily.

Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President

Our indicative theme on Covid-19 Treatment Stocks is up 13% this year, compared to the 4% gain for the S&P 500. While anti-viral therapeutics are quite complex to develop, companies have largely been adapting existing therapies for Covid treatments while also developing new treatment options.

Gilead, Regeneron, Amgen: Covid Treatment Stocks Still Worth Looking At As Vaccine Nears?

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

Regeneron Surges on Coronavirus Treatment Development Efforts

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive preliminary Phase 1/2/3 results Tuesday for a study that evaluated its antibody cocktail REGN-COV2 in non-hospitalized coronavirus patients.  REGN-COV2 is composed of two anti-spike monoclonal antibodies that target the receptor binding domain of the coronavirus and prevent it from docking with host cells.

2 Regeneron Analysts On COVID-19 Antibody Cocktail's Emergency Use Authorization Prospects

In early-stage results, the antibody "cocktail" appears to be efficacious for different types of patients suffering from the disease.

News for Regeneron Pharmaceuticals Stock (REGN)